This review presents only those contributions that have progressed from the bench to the
clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or …

Drug targeting is an attractive new approach to killing malignant cells, thereby leaving
normal tissue unharmed. A decisive breakthrough was the advent of hybridoma technology …

Targeting drugs for cancer therapy with antibodies directed toward tumor cells offers the
hope of selective toxic effects. Thus, the patient would experience fewer side effects, and …

Recombinant immunotoxins consist of Fv regions of tumour-selective antibodies fused to
toxins found in bacteria, plants or fungi. These toxins must be modified to remove normal …

Immunotoxins are formed by chemically linking antibodies to" toxic" polypeptides that
inactivate protein synthesis. These hybrid protein molecules are guided to tumor cells by the …

Immunotoxins (ITs) are chimeric molecules constructed by covalently conjugating
monoclonal antibodies (MoAbs) to plant or bacterial toxins (eg ricin or pseudomonas …

Immunotoxins are composed of a protein toxin connected to a binding ligand such as an
antibody or growth factor. These molecules bind to surface antigens (which internalize) and …

Immunotoxins are a new class of antitumor agents consisting of tumor-selective ligands
(generally monoclonal antibodies [MoAbs]) linked to highly toxic protein molecules that have …

Immunotoxins are proteins that contain a toxin along with an antibody or growth factor that
binds specifically to target cells. Nearly all protein toxins work by enzymatically inhibiting …

Immunotoxins are a novel class of antibody-conjugated therapeutics currently in clinical
development for a variety of malignancies. They consist of an antibody-based targeting …